Speed with confidence in delivery

 

Ibex™ Design is our offering for your preclinical and IND needs through to clinical phase I. It includes a pioneering gene-to-vial package, delivering GMP drug product for your clinical phase 1 trials within 12 months, with an option to supply tox drug product in 9 months. To ensure speed to your milestones, Lonza guarantees the timelines of product supplied*. To further increase predictability for you, we will keep a manufacturing slot reserved for your clinical resupply. Benefit from our proven GS Gene Expression System® bioprocess platform and a holistic development strategy with the endpoint in mind.

*For antibodies and antibody like molecules. From receipt of the gene sequence. Subject to terms and conditions.


  • Does your CDMO stand behind its promises? We do by guaranteeing development & manufacturing timelines.

    Going from gene to IND as fast as possible is a clear objective for most biotech companies like yours. You are under pressure to shorten your timelines and move as quickly as possible: the next round of investment funding may depend on hitting your targets.

    If you are looking to outsource, the available options need to be critically assessed. How can you ensure your service provider stands behind its promises and keeps timing without delays? How do you avoid a situation where you pick a fast service, but where you may not get the quality or quantity you need?

    The answer is simple. Chose a partner who commits on time, quantity and quality. Choose a partner who shares the risks with you. Work with the only CDMO that guarantees* to deliver GMP drug product for your phase 1 trials within 12 months, with an option to supply tox material in 9 months, and in addition ensures a quantity of min. 1kg GMP drug substance material for your phase 1 clinical needs.

    Welcome to Ibex™ Solutions

    Ibex™ Design is a pioneering gene to vial offering delivering GMP drug product for your clinical phase 1 trials within 12 months, with an option to supply tox drug product in 9 months. To ensure speed to your milestones, we guarantee the timelines of product supplied*.

    *For antibodies and antibody like molecules. From receipt of the gene sequence. Subject to terms and conditions.
  • Advancing biotherapeutics from late stage discovery into the clinic is a critical step in drug development. However, developing a new molecule is not only about speed. It is also about managing complexity in the clinical journey by setting relevant milestones. You want to gain a maximum of information on the product as early as possible so you can make the right decisions on time.

    Does your CDMO offers options to meet your milestones? Engage with a team of experts who can help you to plan all key steps of your clinical journey and take your project seamlessly from cell line development to IND and beyond. You can either start with a fast track program from gene to IND in 12 months, or insert a milestone for tox studies at 9 months. For example, performing toxicological studies before entering GMP manufacturing can take time, but such milestone approach minimizes risks. A step-by-step strategy also allows balancing your program’s speed to your funding milestones.

    Welcome to Ibex™ Solutions

    Ibex™ Design is a pioneering gene to vial offering delivering GMP drug product for your clinical phase 1 trials within 12 months, with an option to supply tox drug product in 9 months. To ensure speed to your milestones, we guarantee the timelines of product supplied*.

    *For antibodies and antibody like molecules. From receipt of the gene sequence. Subject to terms and conditions.
  • Progressing from Gene to IND is a clear goal for biotech companies like yours. You need a comprehensive CMC program to hit this milestone: but what does it mean? Where such service offer starts, where does it finish, and how fast can it be? Do 7, 9 or 12 months-programs contain everything you need for your IND submission? Does a fast timeline start from gene sequence or from cell line construction, and does it end with GMP drug substance, GMP drug product or also with an IND ready documentation including stability study results?

    Let’s avoid confusion. It is easy to get clarity by selecting a CMC program that offers both fast timelines and a complete IND package from A to Z: from gene to submission ready CMC package within 12 months, and an option to supply tox drug product in 9 months.

    Welcome to Ibex™ Solutions

    Ibex™ Design is a pioneering gene to vial offering delivering GMP drug product for your clinical phase 1 trials within 12 months, with an option to supply tox drug product in 9 months. To ensure speed to your milestones, we guarantee the timelines of product supplied*.

    *For antibodies and antibody like molecules. From receipt of the gene sequence. Subject to terms and conditions.